Association/NN
between/IN
Interferon-Inducible/JJ
Protein/NN
6/CD
(/(
IFI6/NN
)/)
Polymorphisms/NNS
and/CC
Hepatitis/NN
B/NN
Virus/NN
Clearance/NN
./.
====================
CD8+/JJ
T/NN
cells/NNS
are/VBP
key/JJ
factors/NNS
mediating/VBG
hepatitis/NN
B/NN
virus/NN
(/(
HBV/NN
)/)
clearance/NN
./.
====================
However/RB
,/,
these/DT
cells/NNS
are/VBP
killed/VBN
through/IN
HBV-induced/JJ
apoptosis/NN
during/IN
the/DT
antigen-presenting/JJ
period/NN
in/IN
HBV-induced/JJ
chronic/JJ
liver/NN
disease/NN
(/(
CLD/NN
)/)
patients/NNS
./.
====================
Interferon-inducible/JJ
protein/NN
6/CD
(/(
IFI6/NN
)/)
delays/VBZ
type/NN
I/CD
interferon-induced/JJ
apoptosis/NN
in/IN
cells/NNS
./.
====================
We/PRP
hypothesized/VBD
that/IN
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
in/IN
the/DT
IFI6/NN
could/MD
affect/VB
the/DT
chronicity/NN
of/IN
CLD/NN
./.
====================
The/DT
present/JJ
study/NN
included/VBD
a/DT
discovery/JJ
stage/NN
,/,
in/IN
which/WDT
195/CD
CLD/NN
patients/NNS
,/,
including/VBG
chronic/JJ
hepatitis/NN
B/NN
(/(
HEP/NN
)/)
and/CC
cirrhosis/NN
patients/NNS
and/CC
107/CD
spontaneous/JJ
recovery/NN
(/(
SR/JJ
)/)
controls/VBZ
,/,
were/VBD
analyzed/VBN
./.
====================
The/DT
genotype/JJ
distributions/NNS
of/IN
rs2808426/JJ
(/(
C/NN
>/JJR
T/NN
)/)
and/CC
rs10902662/NN
(/(
C/NN
>/JJR
T/NN
)/)
were/VBD
significantly/RB
different/JJ
between/IN
the/DT
SR/JJ
and/CC
HEP/NN
groups/NNS
(/(
odds/NNS
ratio/RB
[/(
OR/NN
]/)
,/,
6.60/CD
;/:
95/CD
%/NN
confidence/IN
interval/JJ
[/(
CI/NNP
]/)
,/,
1.64/CD
to/TO
26.52/CD
,/,
p/NN
=/JJ
0.008/CD
for/IN
both/DT
SNPs/NNS
)/)
and/CC
between/IN
the/DT
SR/JJ
and/CC
CLD/NN
groups/NNS
(/(
OR/NN
,/,
4.38/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.25/CD
to/TO
15.26/CD
;/:
p/NN
=/JJ
0.021/CD
and/CC
OR/NN
,/,
4.12/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.18/CD
to/TO
14.44/CD
;/:
p/NN
=/JJ
0.027/CD
,/,
respectively/RB
)/)
./.
====================
The/DT
distribution/NN
of/IN
diplotypes/NNS
that/IN
contained/VBD
these/DT
SNPs/NNS
was/VBD
significantly/RB
different/JJ
between/IN
the/DT
SR/JJ
and/CC
HEP/NN
groups/NNS
(/(
OR/NN
,/,
6.58/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.63/CD
to/TO
25.59/CD
;/:
p/NN
=/JJ
0.008/CD
and/CC
OR/NN
,/,
0.15/CD
;/:
95/CD
%/NN
CI/NN
,/,
0.04/CD
to/TO
0.61/CD
;/:
p/NN
=/JJ
0.008/CD
,/,
respectively/RB
)/)
and/CC
between/IN
the/DT
SR/JJ
and/CC
CLD/NN
groups/NNS
(/(
OR/NN
,/,
4.38/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.25/CD
to/TO
15.26/CD
;/:
p/NN
=/JJ
0.021/CD
and/CC
OR/NN
,/,
4.12/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.18/CD
to/TO
14.44/CD
;/:
p/NN
=/JJ
0.027/CD
,/,
respectively/RB
)/)
./.
====================
We/PRP
were/VBD
unable/JJ
to/TO
replicate/VB
the/DT
association/NN
shown/VBN
by/IN
secondary/JJ
enrolled/JJ
samples/NNS
./.
====================
A/DT
large-scale/JJ
validation/NN
study/NN
should/MD
be/VB
performed/VBN
to/TO
confirm/VB
the/DT
association/NN
between/IN
IFI6/NN
and/CC
HBV/NN
clearance/NN
./.
====================
Between/IN
350/CD
and/CC
400/CD
million/NN
people/NN
worldwide/NN
are/VBP
chronically/RB
infected/JJ
with/IN
the/DT
hepatitis/NN
B/NN
virus/NN
(/(
HBV/NN
)/)
[/(
1/CD
,/,
2/CD
]/)
./.
====================
In/IN
most/JJS
HBV-infected/JJ
patients/NNS
,/,
spontaneous/JJ
recovery/NN
(/(
SR/JJ
)/)
by/IN
the/DT
host/NN
immune/JJ
system/NN
is/VBZ
common/JJ
./.
====================
However/RB
,/,
5/CD
%/NN
to/TO
10/CD
%/NN
of/IN
patients/NNS
fail/VBP
to/TO
recover/RB
and/CC
remain/VBP
as/IN
HBV-induced/JJ
chronic/JJ
liver/NN
disease/NN
(/(
CLD/NN
)/)
patients/NNS
[/(
3/CD
]/)
./.
====================
CLD/NN
,/,
including/VBG
HBV-induced/JJ
chronic/JJ
hepatitis/NN
B/NN
(/(
HEP/NN
)/)
and/CC
HBV-induced/JJ
cirrhosis/NN
(/(
CIR/NN
)/)
,/,
is/VBZ
a/DT
major/JJ
cause/VBP
of/IN
hepatocellular/JJ
carcinoma/NN
,/,
which/WDT
can/MD
lead/VB
to/TO
liver-related/JJ
death/NN
[/(
4/CD
]/)
./.
====================
The/DT
high/JJ
mortality/NN
of/IN
CLD/NN
is/VBZ
a/DT
major/JJ
problem/NN
in/IN
HBV-endemic/JJ
countries/NNS
[/(
5/CD
]/)
./.
====================
In/IN
Korea/NN
,/,
which/WDT
is/VBZ
an/DT
HBV/NN
endemic/JJ
area/NN
,/,
more/RBR
than/IN
70/CD
%/NN
of/IN
CLD/NN
patients/NNS
are/VBP
infected/VBN
by/IN
HBV/NN
[/(
6/CD
,/,
7/CD
]/)
./.
====================
CD8+/JJ
T/NN
cells/NNS
are/VBP
key/JJ
factors/NNS
involved/VBN
in/IN
the/DT
chronicity/NN
of/IN
CLD/NN
./.
====================
The/DT
major/JJ
roles/NNS
of/IN
CD8+/JJ
T/NN
cells/NNS
in/IN
HBV/NN
clearance/NN
are/VBP
the/DT
production/NN
of/IN
interferon/NN
(/(
IFN/NN
)/)
-γ/RB
,/,
which/WDT
inhibits/VBZ
HBV/NN
gene/NN
expression/NN
and/CC
the/DT
assembly/NN
of/IN
HBV/NN
RNA-containing/JJ
capsids/NNS
,/,
and/CC
the/DT
induction/NN
of/IN
apoptosis/NN
of/IN
virus-infected/JJ
hepatocytes/NNS
,/,
which/WDT
requires/VBZ
physical/JJ
contact/NN
with/IN
CD8+/JJ
T/NN
cells/NNS
[/(
8-11/CD
]/)
./.
====================
However/RB
,/,
the/DT
CD8+/JJ
T/NN
cells/NNS
of/IN
CLD/NN
patients/NNS
undergo/VBP
activation-induced/JJ
apoptosis/NN
instead/RB
of/IN
proliferation/NN
in/IN
the/DT
presence/NN
of/IN
antigen-presenting/JJ
cells/NNS
[/(
12/CD
,/,
13/CD
]/)
./.
====================
Apoptosis/NN
of/IN
antigen-specific/JJ
CD8+/JJ
T/NN
cells/NNS
in/IN
CLD/NN
patients/NNS
and/CC
lymphocytic/JJ
choriomeningitis/NN
virus/NN
(/(
LCMV/NN
)/)
-infected/JJ
type/NN
I/CD
IFN/NN
receptor-null/JJ
mice/NNS
is/VBZ
mediated/VBN
by/IN
B-cell/NN
lymphoma/NN
(/(
Bcl/JJ
)/)
-2/CD
[/(
12/CD
,/,
14-16/CD
]/)
,/,
indicating/VBG
that/IN
type/NN
I/CD
IFN/NN
is/VBZ
critical/JJ
to/TO
the/DT
survival/NN
of/IN
antigen-specific/JJ
CD8+/JJ
T/NN
cells/NNS
during/IN
the/DT
transition/NN
from/IN
acute/JJ
to/TO
chronic/JJ
HBV/NN
infection/NN
./.
====================
Kolumam/NN
et/FW
al/JJ
./.
====================
[/(
16/CD
]/)
reported/VBD
that/IN
type/NN
I/CD
IFN/NN
acts/VBZ
directly/RB
on/IN
CD8+/JJ
T/NN
cells/NNS
to/TO
allow/VB
clonal/JJ
expansion/NN
and/CC
memory/NN
formation/NN
in/IN
response/NN
to/TO
LCMV/NN
infection/NN
./.
====================
Type/NN
I/CD
IFN/NN
receptor-null/JJ
CD8+/JJ
T/NN
cells/NNS
neither/CC
produce/VBP
antiviral/JJ
molecules/NNS
,/,
including/VBG
IFN-γ/JJ
,/,
granzyme/NN
B/NN
,/,
and/CC
tumor/NN
necrosis/NN
factor/NN
(/(
TNF/NN
)/)
-α/JJ
nor/CC
show/VBP
reduced/VBD
survival/NN
after/IN
antigen-induced/JJ
stimulation/NN
[/(
16/CD
]/)
./.
====================
Type/NN
I/CD
IFN/NN
on/IN
CD8+/JJ
T/NN
cells/NNS
is/VBZ
critical/JJ
for/IN
survival/NN
,/,
proliferation/NN
,/,
and/CC
antiviral/JJ
functions/NNS
[/(
16/CD
]/)
./.
====================
IFNs/NNS
are/VBP
a/DT
well-known/JJ
family/NN
of/IN
cytokines/NNS
with/IN
antiviral/JJ
effects/NNS
[/(
17/CD
,/,
18/CD
]/)
./.
====================
IFNs/NNS
modulate/VBP
cellular/JJ
proliferation/NN
and/CC
stimulate/VBP
immune/JJ
responses/NNS
through/IN
several/JJ
IFN-stimulated/JJ
genes/NNS
(/(
ISGs/NNS
)/)
[/(
19/CD
]/)
./.
====================
IFN-α-inducible/JJ
protein/NN
6/CD
(/(
IFI6/NN
)/)
is/VBZ
a/DT
type/NN
I/CD
ISG/NN
[/(
20-22/NN
]/)
that/IN
maps/VBZ
to/TO
chromosome/NN
1p35/NN
[/(
23/CD
]/)
and/CC
is/VBZ
regulated/VBN
by/IN
the/DT
Janus/NN
tyrosine/NN
kinase/NN
signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
signaling/NN
pathway/NN
[/(
24/CD
]/)
./.
====================
IFI6/CD
is/VBZ
a/DT
mitochondria-targeted/JJ
protein/NN
;/:
it/PRP
inhibits/VBZ
the/DT
release/NN
of/IN
cytochrome/NN
c/NN
from/IN
mitochondria/NN
and/CC
delays/VBZ
the/DT
apoptotic/JJ
process/NN
initiated/VBN
and/CC
transduced/VBD
by/IN
the/DT
TNF-related/JJ
apoptosis-inducing/VBG
ligand/caspase/NN
8/CD
pathway/NN
[/(
25/CD
]/)
./.
====================
The/DT
role/NN
of/IN
IFI6/NN
is/VBZ
strongly/RB
associated/VBN
with/IN
the/DT
immune/JJ
system/NN
,/,
but/CC
its/PRP$
antiviral/JJ
effects/NNS
are/VBP
not/RB
well/RB
known/VBN
[/(
26/CD
]/)
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
hypothesized/VBD
that/IN
IFI6/NN
may/MD
be/VB
a/DT
survival-promoting/VBG
factor/NN
for/IN
CD8+/JJ
T/NN
cells/NNS
and/CC
therefore/RB
a/DT
determinant/JJ
of/IN
the/DT
chronicity/NN
of/IN
HEP/NN
./.
====================
The/DT
frequencies/NNS
of/IN
IFI6/NN
polymorphisms/NNS
in/IN
CLD/NN
patients/NNS
and/CC
SR/JJ
controls/NNS
were/VBD
compared/VBN
using/VBG
logistic/JJ
regression/NN
./.
====================
Subjects/NNS
for/IN
the/DT
case-control/JJ
study/NN
====================
A/DT
discovery/NN
stage/NN
included/VBD
305/CD
blood/NN
samples/NNS
obtained/VBN
from/IN
the/DT
outpatient/JJ
clinic/JJ
of/IN
the/DT
Gastroenterology/NN
Department/JJ
and/CC
from/IN
the/DT
Center/JJ
for/IN
Health/NN
Promotion/NN
of/IN
Ajou/NNP
University/NN
Hospital/JJ
(/(
Suwon/NN
,/,
Korea/NN
)/)
without/IN
gender/NN
or/CC
age/NN
restrictions/NNS
between/IN
March/NN
2002/CD
and/CC
February/JJ
2006/CD
./.
====================
Samples/NNS
were/VBD
derived/VBN
from/IN
genetically/RB
unrelated/JJ
Korean/JJ
patients/NNS
./.
====================
The/DT
experimental/JJ
protocol/NN
was/VBD
approved/VBN
by/IN
the/DT
institutional/JJ
review/NN
board/JJ
./.
====================
Samples/NNS
were/VBD
divided/VBN
into/IN
SR/JJ
control/NN
(/(
n/NN
=/JJ
107/CD
)/)
,/,
HEP/NN
(/(
n/NN
=/JJ
111/CD
)/)
,/,
and/CC
CIR/NN
(/(
n/NN
=/JJ
87/CD
)/)
groups/NNS
,/,
according/VBG
to/TO
serological/JJ
markers/NNS
and/CC
biopsy/NN
results/NNS
./.
====================
Three/CD
samples/NNS
in/IN
the/DT
HEP/NN
group/NN
were/VBD
not/RB
genotype-replicated/VBN
and/CC
were/VBD
excluded/VBN
from/IN
the/DT
analysis/NN
./.
====================
Finally/RB
,/,
107/CD
SR/JJ
control/NN
,/,
108/CD
HEP/NN
,/,
and/CC
87/CD
CIR/NN
patients/NNS
were/VBD
analyzed/VBN
./.
====================
In/IN
the/DT
replication/NN
stage/NN
,/,
736/CD
blood/NN
samples/NNS
were/VBD
collected/VBN
from/IN
Ajou/NNP
University/NN
Hospital/JJ
and/CC
Keiymung/NN
University/NN
(/(
Daegu/NNP
,/,
Korea/NN
)/)
between/IN
February/JJ
2006/CD
and/CC
September/NN
2012/CD
./.
====================
Samples/NNS
were/VBD
derived/VBN
from/IN
genetically/RB
unrelated/JJ
Korean/JJ
patients/NNS
./.
====================
The/DT
experimental/JJ
protocol/NN
was/VBD
approved/VBN
by/IN
the/DT
institutional/JJ
review/NN
board/JJ
./.
====================
Samples/NNS
were/VBD
divided/VBN
into/IN
two/CD
205/CD
SR/JJ
controls/NNS
,/,
437/CD
HEP/NN
patients/NNS
,/,
and/CC
94/CD
CIR/NN
patients/NNS
according/VBG
to/TO
serological/JJ
markers/NNS
and/CC
biopsy/NN
results/NNS
./.
====================
All/DT
samples/NNS
were/VBD
infected/VBN
with/IN
HBV/NN
and/CC
classified/VBN
into/IN
one/CD
of/IN
the/DT
three/CD
groups/NNS
,/,
according/VBG
to/TO
their/PRP$
HBV/NN
infection/NN
status/NN
,/,
clinical/JJ
data/NNS
,/,
and/CC
serological/JJ
profile/NN
,/,
by/IN
a/DT
pathologist/NN
./.
====================
Every/RB
6/CD
months/NNS
for/IN
>/JJ
12/CD
months/NNS
,/,
the/DT
218/CD
patients/NNS
were/VBD
subjected/VBN
to/TO
serological/JJ
tests/NNS
for/IN
serum/NN
levels/NNS
of/IN
hepatitis/NN
B/NN
core/NN
antibody/NN
(/(
Anti-HBc/JJ
II/CD
Reagent/JJ
Kit/NN
;/:
Abbott/NN
Laboratories/NNS
,/,
South/DT
Pasadena/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
hepatitis/NN
B/NN
surface/NN
antigen/NN
(/(
HBsAg/NN
)/)
(/(
Anti-HBs/NNS
;/:
Abbott/NN
Laboratories/NNS
)/)
,/,
and/CC
hepatitis/NN
B/NN
surface/NN
antibody/NN
(/(
HBsAb/NN
)/)
(/(
HBsAg/NN
;/:
Abbott/NN
Laboratories/NNS
)/)
./.
====================
Liver/RB
function/NN
was/VBD
evaluated/VBN
by/IN
measuring/VBG
aspartate/NN
aminotransferase/NN
(/(
AST/NN
)/)
,/,
alanine/NN
aminotransferase/NN
(/(
ALT/NN
)/)
,/,
albumin/NN
,/,
and/CC
bilirubin/NN
levels/NNS
using/VBG
commercially/RB
available/JJ
assays/NNS
./.
====================
All/DT
samples/NNS
showed/VBD
elevated/JJ
ALT/NN
at/IN
least/JJS
once/RB
during/IN
the/DT
follow-up/JJ
period/NN
and/CC
were/VBD
positive/JJ
for/IN
HBV/NN
DNA/NN
,/,
irrespective/JJ
of/IN
hepatitis/NN
B/NN
e/NN
antigen/NN
(/(
HBeAg/NN
)/)
positivity/NN
./.
====================
Patients/NNS
in/IN
the/DT
SR/JJ
group/NN
were/VBD
HBsAg-negative/JJ
,/,
HBeAg-negative/JJ
,/,
anti-HBs-positive/JJ
,/,
and/CC
anti-HBc-positive/JJ
and/CC
had/VBD
recovered/VBN
from/IN
HBV/NN
infection/NN
./.
====================
Patients/NNS
in/IN
the/DT
CLD/NN
group/NN
,/,
including/VBG
those/DT
in/IN
the/DT
HEP/NN
and/CC
CIR/NN
groups/NNS
,/,
were/VBD
HBsAg-positive/JJ
for/IN
more/RBR
than/IN
6/CD
months/NNS
with/IN
elevated/JJ
ALT/NN
and/CC
AST/NN
(/(
≥2/CD
times/NNS
the/DT
normal/JJ
upper/IN
limit/VB
)/)
./.
====================
Samples/NNS
that/DT
were/VBD
positive/JJ
for/IN
anti-hepatitis/JJ
C/NN
virus/NN
(/(
Genedia/NN
HCV/NN
ELISA/NN
3.0/CD
;/:
GreenCross/NNP
,/,
Yoingin/NN
,/,
Korea/NN
)/)
or/CC
anti-immunodeficiency/NN
virus/NN
antibodies/NNS
(/(
HIV/NN
Ag/Ab/NN
combo/NN
;/:
Abbott/NN
Laboratories/NNS
)/)
were/VBD
excluded/VBN
./.
====================
Sample/NN
preparation/NN
====================
All/DT
blood/NN
samples/NNS
were/VBD
stored/VBN
at/IN
-80℃/CD
for/IN
the/DT
handling/NN
of/IN
human/JJ
genomic/JJ
DNA/NN
./.
====================
Genomic/JJ
DNA/NN
was/VBD
purified/VBN
using/VBG
G-DEX/NN
blood/NN
genomic/JJ
DNA/NN
(/(
gDNA/NN
)/)
purification/NN
kits/NNS
(/(
Intron/NN
Biotechnology/NN
Inc./NNP
,/,
Seongnam/JJ
,/,
Korea/NN
)/)
./.
====================
The/DT
gDNA/JJ
for/IN
the/DT
discovery/NN
analysis/NN
was/VBD
quantified/VBN
using/VBG
the/DT
picogreen/NN
dsDNA/JJ
quantification/NN
reagent/JJ
following/VBG
a/DT
standard/JJ
protocol/NN
(/(
Molecular/JJ
Probes/NNS
,/,
Eugene/NN
,/,
OR/NN
,/,
USA/NN
)/)
./.
====================
The/DT
plates/NNS
were/VBD
read/VBN
using/VBG
a/DT
VICTOR3/NN
1420/CD
Multilabel/JJ
counter/NN
(/(
excitation/NN
480/CD
nm/NN
,/,
emission/NN
520/CD
nm/NN
;/:
PerkinElmer/NN
Inc./NNP
,/,
Waltham/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
,/,
and/CC
a/DT
standard/JJ
curve/JJ
for/IN
gDNA/JJ
concentration/NN
was/VBD
generated/VBN
using/VBG
known/VBN
concentrations/NNS
of/IN
lambda/NN
DNA/NN
./.
====================
The/DT
quality/NN
of/IN
the/DT
gDNA/JJ
analyzed/VBD
in/IN
the/DT
replication/NN
stage/NN
was/VBD
determined/VBN
using/VBG
a/DT
NanoDrop/JJ
ND-1000/CD
UV-Vis/NN
Spectrophotometer/NN
(/(
Thermo/DT
,/,
Eugene/NN
,/,
OR/NN
,/,
USA/NN
)/)
./.
====================
Genomic/JJ
DNA/NN
was/VBD
diluted/VBN
to/TO
a/DT
concentration/NN
of/IN
10/CD
ng/µL/NN
in/IN
96-well/JJ
PCR/NN
plates/NNS
./.
====================
Single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
selection/NN
and/CC
genotyping/VBG
====================
In/IN
the/DT
discovery/NN
stage/NN
,/,
six/CD
SNPs/NNS
were/VBD
selected/VBN
from/IN
a/DT
public/JJ
SNP/NN
database/NN
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/snp//JJ
)/)
for/IN
the/DT
genotyping/VBG
assay/NN
:/:
1/CD
)/)
polymorphic/JJ
in/IN
Chinese/JJ
and/CC
Japanese/JJ
;/:
2/CD
)/)
tag/NN
SNPs/NNS
in/IN
Asian/JJ
;/:
3/CD
)/)
might/MD
have/VBP
functionality/NN
in/IN
protein/NN
or/CC
expression/NN
level/NN
./.
====================
The/DT
selected/VBN
SNPs/NNS
were/VBD
1/CD
)/)
one/CD
SNP/NN
in/IN
the/DT
5/CD
'/``
flanking/JJ
region/NN
(/(
rs2808426/NN
)/)
;/:
2/CD
)/)
three/CD
intronic/JJ
SNPs/NNS
(/(
rs10902662/NN
,/,
rs1316896/RB
,/,
and/CC
rs4908351/NN
)/)
;/:
3/LS
)/)
one/CD
SNP/NN
in/IN
the/DT
untranslated/JJ
region/NN
(/(
rs1141747/NN
)/)
;/:
and/CC
4/CD
)/)
one/CD
SNP/NN
in/IN
the/DT
3/CD
'/``
flanking/JJ
region/NN
(/(
rs2808430/CD
)/)
./.
====================
The/DT
genotyping/JJ
was/VBD
performed/VBN
using/VBG
the/DT
GoldenGate/NN
kit/NN
according/VBG
to/TO
a/DT
standard/JJ
protocol/NN
(/(
Illumina/NN
Inc./NNP
,/,
San/JJ
Diego/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
Oligos/NNS
were/VBD
amplified/VBN
by/IN
allele-specific/JJ
primer/NN
extension/NN
./.
====================
After/IN
hybridization/NN
to/TO
a/DT
sentrix/NN
array/NN
matrix/NN
,/,
signal/NN
intensities/NNS
were/VBD
read/VBN
by/IN
BeadArray/NN
Reader/NN
(/(
Illumina/NN
Inc./NNP
)/)
./.
====================
Genotyping/VBG
analysis/NN
was/VBD
performed/VBN
using/VBG
GenomeStudio/NN
software/JJ
(/(
version/NN
1.5.16/CD
;/:
Illumina/NN
Inc./NNP
)/)
./.
====================
In/IN
the/DT
replication/NN
stage/NN
,/,
rs2808426/NN
,/,
which/WDT
was/VBD
identified/VBN
in/IN
the/DT
discovery/NN
stage/NN
,/,
was/VBD
genotyped/VBN
using/VBG
Taqman/JJ
technology/NN
./.
====================
The/DT
probes/NNS
were/VBD
labeled/VBN
with/IN
FAM/NN
or/CC
VIC/NN
dye/NN
at/IN
the/DT
5/CD
'/``
end/NN
and/CC
a/DT
minor/JJ
groove/NN
binder/NN
and/CC
nonfluorescent/JJ
quencher/RB
at/IN
the/DT
3/CD
'/``
end/NN
./.
====================
All/DT
reactions/NNS
were/VBD
performed/VBN
following/VBG
the/DT
supplier/NN
's/POS
protocol/NN
./.
====================
SNP/NN
genotyping/VBG
reactions/NNS
were/VBD
performed/VBN
on/IN
the/DT
ABI/NN
PRISM/NN
7900HT/CD
real-time/VBP
PCR/NN
system/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
After/IN
the/DT
PCR/NN
amplification/NN
,/,
allelic/JJ
discrimination/NN
was/VBD
performed/VBN
on/IN
the/DT
ABI/NN
PRISM/NN
7900HT/CD
./.
====================
Allele/DT
calls/NNS
were/VBD
made/VBN
with/IN
SDS/NN
v2.4/CD
software/JJ
(/(
Applied/VBN
Biosystems/NNS
)/)
./.
====================
Statistical/JJ
analysis/NN
====================
The/DT
genetic/JJ
models/NNS
for/IN
the/DT
association/NN
test/NN
were/VBD
divided/VBN
according/VBG
to/TO
additive/JJ
(/(
AA/NN
vs./CC
Aa/NN
vs./CC
aa/NN
)/)
,/,
dominant/JJ
(/(
AA/NN
vs./CC
Aa/NN
plus/CC
aa/NN
)/)
,/,
and/CC
recessive/JJ
(/(
AA/NN
plus/CC
Aa/NN
vs./CC
aa/NN
)/)
models/NNS
./.
====================
The/DT
χ2/NN
test/NN
was/VBD
used/VBN
to/TO
assess/VB
the/DT
Hardy-Weinberg/JJ
equilibrium/NN
(/(
HWE/NN
)/)
in/IN
the/DT
SR/JJ
,/,
HEP/NN
,/,
CIR/NN
,/,
and/CC
CLD/NN
groups/NNS
./.
====================
The/DT
difference/NN
between/IN
groups/NNS
was/VBD
determined/VBN
by/IN
the/DT
odds/NNS
ratio/NN
(/(
OR/NN
)/)
./.
====================
ORs/NNS
were/VBD
presented/VBN
with/IN
95/CD
%/NN
confidence/NN
intervals/NNS
(/(
95/CD
%/NN
CIs/NNS
)/)
and/CC
adjusted/VBN
for/IN
age/NN
and/CC
sex/NN
./.
====================
Each/DT
individual/JJ
haplotype/NN
was/VBD
inferred/VBN
from/IN
the/DT
EM/NN
algorithm/NN
using/VBG
the/DT
SAS/NN
haplotype/NN
procedure/NN
(/(
version/NN
9.1/CD
;/:
SAS/NN
Institute/JJ
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NN
)/)
./.
====================
Linkage/JJ
disequilibrium/NN
(/(
LD/NN
)/)
blocks/VBZ
were/VBD
checked/VBN
by/IN
the/DT
Gabriel/JJ
method/NN
using/VBG
Haploview/NN
software/JJ
(/(
version/NN
4.2/CD
;/:
Broad/JJ
Institute/JJ
,/,
Cambridge/NN
,/,
MA/NN
,/,
USA/NN
)/)
./.
====================
All/DT
statistical/JJ
tests/NNS
were/VBD
performed/VBN
using/VBG
SAS/NN
software/JJ
,/,
and/CC
the/DT
significance/NN
level/NN
was/VBD
set/NN
at/IN
p/NN
</JJR
0.05/CD
./.
====================
The/DT
probability/NN
values/NNS
obtained/VBN
were/VBD
corrected/VBN
for/IN
multiple/JJ
testing/VBG
by/IN
using/VBG
Bonferroni/NNP
's/POS
correction/NN
and/CC
permutation/NN
test/NN
./.
====================
Bonferroni/NNS
's/POS
p-value/NN
for/IN
reaching/VBG
significance/NN
was/VBD
0.025/CD
(/(
0.05/2/CD
)/)
./.
====================
The/DT
Plink/NN
program/NN
was/VBD
used/VBN
to/TO
confirm/VB
the/DT
results/NNS
and/CC
permutation/NN
test/NN
(/(
n/NN
=/JJ
100,000/CD
;/:
http/NN
:/:
//pngu.mgh.harvard.edu/~purcell/plink//JJ
)/)
./.
====================
The/DT
fate/JJ
of/IN
the/DT
patients/NNS
infected/JJ
with/IN
HBV/NN
was/VBD
determined/VBN
by/IN
several/JJ
factors/NNS
,/,
including/VBG
host/NN
immune/JJ
reactions/NNS
./.
====================
Type/NN
I/CD
IFNs/NNS
play/VBP
a/DT
key/JJ
role/NN
in/IN
the/DT
defense/NN
against/IN
HBV/NN
infection/NN
and/CC
therefore/RB
in/IN
the/DT
prevention/NN
of/IN
chronic/JJ
hepatitis/NN
./.
====================
IFI6/CD
is/VBZ
induced/VBN
by/IN
type/NN
I/CD
IFN/NN
./.
====================
To/TO
test/VB
the/DT
effect/NN
of/IN
IFI6/NN
polymorphisms/NNS
on/IN
the/DT
chronicity/NN
of/IN
HEP/NN
,/,
samples/NNS
were/VBD
collected/VBN
from/IN
SR/JJ
controls/NNS
(/(
HBsAg-/NN
)/)
,/,
who/WP
recovered/VBD
from/IN
HBV/NN
infection/NN
without/IN
any/DT
treatment/NN
,/,
and/CC
CLD/NN
patients/NNS
,/,
including/VBG
HEP/NN
and/CC
CIR/NN
groups/NNS
(/(
HBsAg+/JJ
)/)
,/,
who/WP
were/VBD
at/IN
risk/NN
of/IN
HBV/NN
infection/NN
./.
====================
To/TO
analyze/VB
first/JJ
whether/IN
variations/NNS
in/IN
the/DT
IFI6/NN
gene/NN
were/VBD
associated/VBN
with/IN
the/DT
susceptibility/NN
to/TO
HEP/NN
in/IN
the/DT
Korean/JJ
population/NN
,/,
107/CD
controls/VBZ
in/IN
the/DT
SR/JJ
group/NN
,/,
108/CD
patients/NNS
in/IN
the/DT
HEP/NN
group/NN
,/,
and/CC
95/CD
patients/NNS
in/IN
the/DT
CIR/NN
group/NN
were/VBD
analyzed/VBN
for/IN
six/CD
SNPs/NNS
of/IN
IFI6/NN
(/(
n/NN
=/JJ
302/CD
)/)
./.
====================
The/DT
characteristics/NNS
of/IN
the/DT
study/NN
subjects/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
In/IN
the/DT
first/JJ
phase/NN
or/CC
discovery/NN
stage/NN
,/,
four/CD
out/IN
of/IN
six/CD
SNPs/NNS
(/(
rs1316896/CD
,/,
rs4908351/NN
,/,
rs1141747/NN
,/,
and/CC
rs2808430/NN
)/)
were/VBD
monomorphic/JJ
./.
====================
Genetic/JJ
variants/NNS
of/IN
rs2808426/NN
and/CC
rs10902662/NN
did/VBD
not/RB
show/VB
evidence/NN
of/IN
departure/NN
from/IN
minor/JJ
allele/NN
frequency/NN
and/CC
HWE/NN
in/IN
either/CC
of/IN
the/DT
groups/NNS
(/(
p/NN
>/JJR
0.05/CD
)/)
./.
====================
Two/CD
genotypes/NNS
had/VBD
minor/JJ
allele/NN
frequencies/NNS
greater/JJR
than/IN
1/CD
%/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
results/NNS
of/IN
the/DT
genotype/NN
analysis/NN
showed/VBD
that/IN
the/DT
CC/NN
genotype/NN
was/VBD
the/DT
most/JJS
common/JJ
in/IN
the/DT
rs2808426/NN
and/CC
rs10902662/NN
polymorphisms/NNS
in/IN
all/DT
groups/NNS
./.
====================
To/TO
analyze/VB
the/DT
genetic/JJ
association/NN
between/IN
IFI6/NN
polymorphisms/NNS
and/CC
clearance/NN
from/IN
CLD/NN
,/,
HEP/NN
,/,
and/CC
CIR/NN
,/,
multiple/JJ
logistic/JJ
regression/NN
analysis/NN
with/IN
adjustment/JJ
for/IN
gender/NN
and/CC
age/NN
was/VBD
performed/VBN
./.
====================
In/IN
the/DT
comparison/NN
between/IN
SR/JJ
and/CC
CLD/NN
patients/NNS
,/,
rs2808426/NN
was/VBD
associated/VBN
with/IN
CLD/NN
in/IN
a/DT
recessive/JJ
model/NN
(/(
OR/NN
,/,
4.38/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.25/CD
to/TO
15.26/CD
;/:
p/NN
=/JJ
0.021/CD
)/)
./.
====================
In/IN
addition/NN
,/,
rs10902662/NN
showed/VBD
significant/JJ
differences/NNS
between/IN
the/DT
SR/JJ
and/CC
CLD/NN
groups/NNS
in/IN
a/DT
recessive/JJ
model/NN
(/(
OR/NN
,/,
4.12/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.18/CD
to/TO
14.44/CD
;/:
p/NN
=/JJ
0.027/CD
)/)
./.
====================
After/IN
the/DT
permutation/NN
test/NN
,/,
the/DT
rs2808426/NN
and/CC
rs10902662/NN
SNPs/NNS
still/RB
had/VBD
significant/JJ
correlations/NNS
(/(
p/NN
</JJR
0.026/CD
)/)
./.
====================
After/IN
Bonferroni/NNP
's/POS
correction/NN
,/,
only/RB
rs2808426/NN
had/VBD
significant/JJ
correlations/NNS
(/(
p/NN
=/JJ
0.042/CD
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
Comparison/NN
between/IN
the/DT
SR/JJ
and/CC
HEP/NN
groups/NNS
showed/VBD
that/IN
the/DT
IFI6/NN
SNPs/NNS
rs2808426/NN
and/CC
rs10902662/NN
in/IN
the/DT
promoter/NN
region/NN
were/VBD
associated/VBN
with/IN
a/DT
higher/JJR
risk/NN
that/DT
correlated/VBD
with/IN
the/DT
homozygous/JJ
variant/JJ
TT/NN
genotype/NN
in/IN
a/DT
recessive/JJ
model/NN
(/(
OR/NN
,/,
6.60/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.64/CD
to/TO
26.52/CD
;/:
p/NN
=/JJ
0.008/CD
)/)
./.
====================
After/IN
the/DT
permutation/NN
test/NN
,/,
the/DT
rs2808426/NN
and/CC
rs10902662/NN
SNPs/NNS
still/RB
had/VBD
significant/JJ
correlations/NNS
(/(
p/NN
=/JJ
0.001/CD
in/IN
both/DT
genotype/JJ
analyses/NNS
)/)
,/,
which/WDT
were/VBD
maintained/VBN
after/IN
Bonferroni/NNP
's/POS
correction/NN
(/(
p/NN
=/JJ
0.016/CD
in/IN
both/DT
genotype/JJ
analyses/NNS
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
results/NNS
of/IN
the/DT
multiple/JJ
logistic/JJ
regression/NN
analysis/NN
comparing/VBG
the/DT
SR/JJ
and/CC
CIR/NN
groups/NNS
showed/VBD
that/IN
the/DT
rs2808426/NN
and/CC
rs10902662/NN
SNPs/NNS
were/VBD
not/RB
associated/VBN
in/IN
all/DT
genetic/JJ
models/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
possible/JJ
genetic/JJ
linkage/NN
between/IN
the/DT
rs2808426/NN
and/CC
rs10902662/NN
polymorphisms/NNS
in/IN
the/DT
protection/NN
against/IN
chronic/JJ
HBV/NN
infection/NN
was/VBD
examined/VBN
./.
====================
LD/NN
blocks/VBZ
were/VBD
constructed/VBN
by/IN
the/DT
Gabriel/JJ
method/NN
using/VBG
Haploview/NN
software/JJ
./.
====================
The/DT
complete/JJ
LD/NN
block/VBP
consisted/JJ
of/IN
rs2808426/NN
and/CC
rs10902662/NN
and/CC
showed/VBD
a/DT
pairwise/JJ
|D'|/NN
=/JJ
1/CD
and/CC
r2/NN
=/JJ
0.942/CD
,/,
which/WDT
reflect/VBP
strong/JJ
LD/NN
./.
====================
The/DT
variants/NNS
across/IN
IFI6/NN
consisted/VBD
of/IN
a/DT
single/JJ
LD/NN
block/VBP
structure/NN
composed/VBN
of/IN
two/CD
haplotypes/NNS
(/(
HTs/NNS
)/)
./.
====================
The/DT
diplotype/JJ
consisted/VBD
of/IN
HT1/NN
C-C/NN
(/(
C/NN
allele/NN
of/IN
rs2808426/NN
;/:
C/NN
allele/NN
of/IN
rs10902662/NN
)/)
and/CC
HT2/NN
T-T/NN
(/(
T/NN
allele/NN
of/IN
rs2808426/NN
;/:
T/NN
allele/NN
of/IN
rs10902662/NN
)/)
./.
====================
The/DT
results/NNS
of/IN
the/DT
HT/NN
estimation/NN
showed/VBD
that/IN
the/DT
CC/NN
and/CC
TT/NN
haplotypes/NNS
accounted/VBN
for/IN
over/IN
99/CD
%/NN
distribution/NN
in/IN
all/DT
groups/NNS
./.
====================
According/VBG
to/TO
three/CD
genetic/JJ
models/NNS
,/,
estimated/VBN
HTs/NNS
were/VBD
used/VBN
for/IN
diplotype/JJ
analysis/NN
by/IN
logistic/JJ
regression/NN
,/,
adjusting/VBG
for/IN
age/NN
and/CC
sex/NN
./.
====================
In/IN
the/DT
recessive/JJ
model/NN
,/,
HT1/NN
frequency/NN
was/VBD
significantly/RB
different/JJ
between/IN
the/DT
SR/JJ
and/CC
the/DT
CLD/NN
(/(
OR/NN
,/,
0.021/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.25/CD
to/TO
15.26/CD
;/:
p/NN
=/JJ
0.021/CD
)/)
and/CC
HEP/NN
(/(
OR/NN
,/,
6.67/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.64/CD
to/TO
26.52/CD
;/:
p/NN
=/JJ
0.008/CD
)/)
groups/NNS
./.
====================
Analysis/NN
of/IN
the/DT
HT2/NN
diplotype/JJ
showed/VBD
a/DT
significant/JJ
difference/NN
between/IN
the/DT
SR/JJ
and/CC
HEP/NN
(/(
OR/NN
,/,
0.15/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.64/CD
to/TO
26.52/CD
;/:
p/NN
=/JJ
0.008/CD
)/)
and/CC
CLD/NN
(/(
OR/NN
,/,
0.24/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.18/CD
to/TO
14.44/CD
;/:
p/NN
=/JJ
0.027/CD
)/)
groups/NNS
in/IN
the/DT
dominant/JJ
model/NN
(/(
Table/JJ
3/CD
)/)
./.
====================
All/DT
diplotype/JJ
p-values/NNS
remained/VBD
significant/JJ
after/IN
the/DT
permutation/NN
test/NN
(/(
p/NN
</JJR
0.022/CD
)/)
,/,
and/CC
with/IN
the/DT
exception/NN
of/IN
HT2/NN
in/IN
the/DT
SR/JJ
and/CC
CLD/NN
groups/NNS
,/,
almost/RB
all/DT
of/IN
the/DT
diplotype/JJ
p-values/NNS
remained/VBD
significant/JJ
after/IN
Bonferroni/NNP
's/POS
correction/NN
(/(
p/NN
</JJR
0.042/CD
)/)
./.
====================
To/TO
replicate/VB
the/DT
significant/JJ
associations/NNS
of/IN
the/DT
SNP/NN
rs2808426/NN
,/,
736/CD
samples/NNS
,/,
consisting/VBG
of/IN
205/CD
SR/JJ
,/,
437/CD
HEP/NN
,/,
and/CC
94/CD
CIR/NN
patients/NNS
,/,
were/VBD
collected/VBN
./.
====================
The/DT
clinical/JJ
information/NN
of/IN
the/DT
patients/NNS
included/VBD
in/IN
the/DT
analysis/NN
is/VBZ
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
second-stage/JJ
genotyping/VBG
was/VBD
performed/VBN
using/VBG
the/DT
Taqman/JJ
assay/NN
./.
====================
The/DT
association/NN
of/IN
rs2808426/NN
with/IN
CLD/NN
was/VBD
assessed/VBN
using/VBG
the/DT
three/CD
genetic/JJ
models/NNS
,/,
and/CC
multiple/JJ
logistic/JJ
regression/NN
with/IN
adjustment/JJ
for/IN
gender/NN
and/CC
age/NN
was/VBD
used/VBN
as/IN
the/DT
first-stage/JJ
analysis/NN
./.
====================
The/DT
results/NNS
of/IN
the/DT
genotype/NN
analysis/NN
of/IN
the/DT
second/JJ
set/NN
of/IN
samples/NNS
in/IN
association/NN
with/IN
CLD/NN
are/VBP
summarized/VBN
in/IN
Table/JJ
4/CD
./.
====================
The/DT
significance/NN
of/IN
the/DT
results/NNS
of/IN
the/DT
first/JJ
genotype/NN
analysis/NN
was/VBD
not/RB
maintained/VBN
in/IN
the/DT
second/JJ
genotype/NN
analysis/NN
./.
====================
Furthermore/RB
,/,
no/DT
significant/JJ
associations/NNS
were/VBD
detected/VBN
in/IN
a/DT
meta-analysis/NN
of/IN
the/DT
first-stage/JJ
and/CC
second-stage/JJ
samples/NNS
(/(
Table/JJ
4/CD
)/)
./.
====================
The/DT
rs2808426/NN
and/CC
rs10902662/NN
SNPs/NNS
are/VBP
located/JJ
in/IN
the/DT
5/CD
'/``
flanking/JJ
region/NN
and/CC
the/DT
first/JJ
intron/NN
of/IN
the/DT
IFI6/NN
gene/NN
,/,
respectively/RB
./.
====================
These/DT
SNPs/NNS
by/IN
themselves/DT
are/VBP
known/VBN
to/TO
regulate/VB
gene/NN
expression/NN
by/IN
causing/VBG
alternative/JJ
splicing/NN
or/CC
by/IN
changing/VBG
the/DT
binding/NN
to/TO
a/DT
transcription/NN
factor/NN
or/CC
microRNA/NN
[/(
21/CD
]/)
./.
====================
The/DT
presence/NN
of/IN
the/DT
rs2808426/NN
SNP/NN
in/IN
the/DT
promoter/NN
region/NN
of/IN
IFI6/NN
led/VBD
us/PRP
to/TO
screen/VB
for/IN
transcription/NN
factors/NNS
with/IN
binding/VBG
sites/NNS
near/JJ
or/CC
on/IN
rs2808426/NN
(/(
C/NN
>/JJR
T/NN
)/)
./.
====================
The/DT
binding/VBG
of/IN
several/JJ
transcription/NN
factors/NNS
,/,
including/VBG
isoforms/NNS
of/IN
the/DT
glucocorticoid/NN
receptor/NN
α/RB
,/,
STAT4/NN
,/,
v-ets/NNS
erythroblastosis/NN
virus/NN
E26/NN
oncogene/NN
homolog/NN
1/CD
(/(
ETS1/NN
)/)
,/,
and/CC
ETS2/NN
,/,
to/TO
the/DT
protective/JJ
allele/NN
(/(
C/NN
)/)
was/VBD
predicted/VBN
by/IN
ALLGEN/NN
PROMO/NN
(/(
version/NN
3.0.2/CD
;/:
http/RB
:/:
//alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi/NNP
?/.
dirDB=TF_8.3/RB
)/)
[/(
27/CD
]/)
./.
====================
Interestingly/RB
,/,
the/DT
binding/NN
of/IN
ETS1/NN
to/TO
the/DT
region/NN
containing/VBG
rs2808426/NN
T/NN
was/VBD
not/RB
predicted/VBN
./.
====================
Differential/JJ
binding/NN
of/IN
ETS1/NN
according/VBG
to/TO
the/DT
genotype/NN
of/IN
rs2808426/NN
may/MD
affect/VB
the/DT
expression/NN
of/IN
IFI6/NN
./.
====================
IFI6/CD
expression/NN
by/IN
type/NN
I/CD
IFNs/NNS
triggers/VBZ
the/DT
formation/NN
of/IN
IFN-stimulated/JJ
gene/NN
factor/NN
3/CD
(/(
ISGF3/NN
)/)
complexes/NNS
containing/VBG
activated/VBN
STAT1/STAT2/NN
and/CC
IFN/NN
regulatory/JJ
factor/NN
9/CD
and/CC
their/PRP$
translocation/NN
into/IN
the/DT
nucleus/NN
,/,
where/WRB
they/PRP
bind/VBP
to/TO
the/DT
tandem/JJ
IFN-stimulated/JJ
regulatory/JJ
element/NN
(/(
ISRE/NN
)/)
in/IN
the/DT
promoter/NN
of/IN
IFI6/NN
[/(
21/CD
,/,
28-31/CD
]/)
./.
====================
Tandem/JJ
binding/VBG
of/IN
ISGF3/NN
to/TO
the/DT
ISRE/NN
is/VBZ
required/VBN
for/IN
maximum/JJ
expression/NN
of/IN
IFI6/NN
[/(
32/CD
]/)
,/,
and/CC
the/DT
promoter/NN
region/NN
,/,
including/VBG
rs2808426/NN
,/,
enhances/VBZ
IFI6/NN
expression/NN
more/RBR
than/IN
the/DT
ISRE/NN
region/NN
alone/RB
[/(
21/CD
]/)
./.
====================
The/DT
ISGF3-binding/JJ
site/NN
for/IN
the/DT
ISRE/NN
is/VBZ
separated/VBN
from/IN
the/DT
ETS1-binding/JJ
site/NN
by/IN
about/RB
1.35/CD
kb/NN
./.
====================
The/DT
transcription/NN
factor/NN
ETS1/NN
may/MD
regulate/VB
the/DT
expression/NN
of/IN
intracellular/JJ
adhesion/NN
molecule-1/NN
by/IN
protein-protein/JJ
interaction/NN
with/IN
STAT1/NN
,/,
which/WDT
is/VBZ
a/DT
component/NN
of/IN
ISGF3/NN
[/(
33/CD
]/)
./.
====================
Overexpression/NN
of/IN
ETS1/NN
in/IN
the/DT
MCF-7/NN
breast/NN
cancer/NN
cell/NN
line/NN
enhances/VBZ
the/DT
expression/NN
of/IN
IFI6/NN
up/IN
to/TO
18.4-fold/JJ
[/(
34/CD
]/)
./.
====================
These/DT
data/NNS
led/VBD
us/PRP
to/TO
speculate/VB
that/IN
the/DT
interaction/NN
between/IN
ETS1/NN
and/CC
STAT1/NN
in/IN
the/DT
ISGF3/NN
complex/NN
may/MD
increase/VB
the/DT
expression/NN
of/IN
IFI6/NN
./.
====================
The/DT
present/JJ
study/NN
investigated/VBD
the/DT
association/NN
between/IN
the/DT
rs2808426/NN
and/CC
rs10902662/NN
polymorphisms/NNS
of/IN
the/DT
IFI6/NN
gene/NN
and/CC
the/DT
clearance/NN
of/IN
HBV/NN
in/IN
the/DT
Korean/JJ
population/NN
by/IN
multistage/JJ
comparison/NN
between/IN
the/DT
SR/JJ
and/CC
CLD/NN
groups/NNS
,/,
including/VBG
the/DT
HEP/NN
and/CC
CIR/NN
groups/NNS
./.
====================
In/IN
the/DT
first/JJ
stage/NN
of/IN
the/DT
analysis/NN
,/,
significant/JJ
associations/NNS
between/IN
the/DT
rs2808426/NN
and/CC
rs10902662/NN
polymorphism/NN
genotypes/NNS
and/CC
diplotypes/NNS
were/VBD
detected/VBN
./.
====================
A/DT
risk/NN
that/DT
was/VBD
associated/VBN
with/IN
the/DT
TT/NN
genotype/NN
in/IN
rs2808426/NN
and/CC
rs10902662/NN
was/VBD
detected/VBN
in/IN
the/DT
comparison/NN
between/IN
the/DT
SR/JJ
and/CC
the/DT
CLD/NN
and/CC
HEP/NN
groups/NNS
./.
====================
Strong/JJ
LD/NN
was/VBD
found/VBN
between/IN
the/DT
SNPs/NNS
rs2808426/NN
and/CC
rs10902662/NN
,/,
containing/VBG
most/JJS
of/IN
the/DT
promoter/NN
region/NN
./.
====================
In/IN
addition/NN
,/,
diplotype/JJ
analysis/NN
showed/VBD
that/IN
the/DT
C-C/NN
HT/NN
was/VBD
associated/VBN
with/IN
a/DT
higher/JJR
chance/NN
of/IN
SR/JJ
than/IN
the/DT
T-T/T-T/NN
diplotype/JJ
and/CC
that/IN
the/DT
C-C/NN
HT/NN
had/VBD
a/DT
protective/JJ
effect/NN
./.
====================
The/DT
results/NNS
of/IN
the/DT
first-stage/JJ
analysis/NN
suggested/VBD
that/IN
rs2808426/NN
and/CC
rs10902662/NN
may/MD
serve/VB
as/IN
candidate/NN
genetic/JJ
screening/NN
markers/NNS
for/IN
HBV/NN
clearance/NN
or/CC
that/DT
causative/JJ
variants/NNS
that/IN
are/VBP
responsible/JJ
for/IN
HBV/NN
clearance/NN
may/MD
be/VB
present/JJ
in/IN
this/DT
LD/NN
block/VBP
./.
====================
The/DT
association/NN
between/IN
IFI6/NN
polymorphisms/NNS
and/CC
HBV-induced/JJ
chronic/JJ
disease/NN
suggest/VBP
that/IN
these/DT
polymorphisms/NNS
might/MD
change/NN
the/DT
expression/NN
level/NN
of/IN
IFI6/NN
according/VBG
to/TO
transcription/NN
factor/NN
binding/NN
./.
====================
Therefore/RB
,/,
an/DT
increase/NN
in/IN
IFI6/NN
expression/NN
that/WDT
is/VBZ
associated/VBN
with/IN
polymorphisms/NNS
of/IN
the/DT
gene/NN
could/MD
inhibit/VB
the/DT
release/NN
of/IN
cytochrome/NN
c/NN
from/IN
mitochondria/NN
and/CC
block/VBP
the/DT
transmission/NN
of/IN
the/DT
apoptosis/NN
signals/NNS
through/IN
Bim/NN
in/IN
HBV-specific/JJ
CD8+/JJ
T/NN
cells/NNS
./.
====================
HBV-specific/JJ
CD8+/JJ
T/NN
cells/NNS
would/MD
thus/RB
escape/VBP
from/IN
antigen-induced/JJ
apoptosis/NN
,/,
proliferate/VBP
,/,
and/CC
then/RB
differentiate/VBP
into/IN
activated/VBN
CD8+/JJ
T/NN
cells/NNS
to/TO
eliminate/VB
HBV/NN
from/IN
the/DT
host/NN
./.
====================
The/DT
results/NNS
of/IN
the/DT
first-stage/JJ
analysis/NN
suggested/VBD
that/IN
IFI6/NN
polymorphisms/NNS
play/VBP
a/DT
significant/JJ
role/NN
./.
====================
In/IN
previous/JJ
studies/NNS
,/,
CD8+/JJ
T/NN
cell-related/JJ
gene/NN
polymorphisms/NNS
,/,
such/JJ
as/IN
those/DT
of/IN
secreted/VBN
phosphoprotein/NN
1/CD
,/,
interleukin-18/IN
,/,
and/CC
cyclin/NN
D2/NN
,/,
were/VBD
reported/VBN
to/TO
affect/VB
the/DT
natural/JJ
course/NN
of/IN
chronic/JJ
HBV/NN
infections/NNS
in/IN
the/DT
Korean/JJ
population/NN
,/,
but/CC
the/DT
effect/NN
of/IN
their/PRP$
genetic/JJ
association/NN
is/VBZ
minor/JJ
(/(
OR/NN
,/,
0.69/CD
to/TO
1.44/CD
)/)
[/(
35/CD
,/,
36/CD
]/)
./.
====================
Furthermore/RB
,/,
genomewide/NN
association/NN
studies/NNS
of/IN
human/JJ
leukocyte/NN
antigen/NN
(/(
HLA/NN
)/)
region/NN
polymorphisms/NNS
,/,
including/VBG
HLA-DPA1/NN
,/,
HLA-DPB1/NN
,/,
and/CC
HLA-DQ/NN
,/,
demonstrated/VBD
their/PRP$
association/NN
with/IN
the/DT
chronicity/NN
of/IN
HBV/NN
[/(
37-43/CD
]/)
./.
====================
In/IN
our/PRP$
first-stage/JJ
analysis/NN
,/,
the/DT
protective/JJ
effect/NN
of/IN
the/DT
rs2808426/NN
and/CC
rs10902662/NN
polymorphisms/NNS
was/VBD
stronger/JJR
than/IN
that/DT
reported/VBD
previously/RB
in/IN
studies/NNS
addressing/VBG
the/DT
association/NN
with/IN
HBV/NN
(/(
OR/NN
,/,
6.60/CD
)/)
./.
====================
The/DT
genotype/NN
and/CC
diplotype/JJ
distribution/NN
in/IN
both/CC
groups/NNS
remained/VBD
significant/JJ
after/IN
multiple/JJ
testing/VBG
by/IN
Bonferroni/NN
's/POS
correction/NN
and/CC
permutation/NN
test/NN
./.
====================
These/DT
results/NNS
might/MD
support/VB
that/DT
genetic/JJ
variation/NN
in/IN
IFI6/NN
affects/VBZ
the/DT
clearance/NN
of/IN
HBV/NN
./.
====================
A/DT
second/JJ
set/NN
of/IN
samples/NNS
was/VBD
used/VBN
to/TO
replicate/VB
the/DT
results/NNS
of/IN
the/DT
first-stage/JJ
analysis/NN
./.
====================
However/RB
,/,
in/IN
the/DT
second/JJ
association/NN
analysis/NN
,/,
the/DT
comparison/NN
of/IN
the/DT
SR/JJ
and/CC
the/DT
HEP/NN
and/CC
CIR/NN
groups/NNS
did/VBD
not/RB
yield/VB
significant/JJ
results/NNS
,/,
even/RB
when/WRB
merging/VBG
the/DT
first-/JJ
and/CC
second-stage/JJ
samples/NNS
in/IN
a/DT
meta-analysis/NN
./.
====================
This/DT
could/MD
have/VB
been/VBN
due/JJ
to/TO
variation/NN
in/IN
the/DT
sampling/JJ
cohort/NN
,/,
environmental/JJ
interactions/NNS
,/,
inadequate/JJ
statistical/JJ
power/JJR
,/,
or/CC
gene/NN
interactions/NNS
[/(
1/CD
,/,
44-49/CD
]/)
./.
====================
Furthermore/RB
,/,
information/NN
on/IN
factors/NNS
important/JJ
for/IN
the/DT
progression/NN
of/IN
liver/NN
disease/NN
was/VBD
lacking/VBG
in/IN
the/DT
samples/NNS
analyzed/VBD
,/,
such/JJ
as/IN
data/NNS
on/IN
alcohol/NN
consumption/NN
[/(
50/CD
]/)
./.
====================
Although/IN
our/PRP$
data/NNS
could/MD
not/RB
be/VB
reproduced/VBN
,/,
the/DT
results/NNS
showing/VBG
an/DT
association/NN
between/IN
IFI6/NN
polymorphisms/NNS
and/CC
HBV/NN
chronicity/NN
are/VBP
significant/JJ
./.
====================
Our/PRP$
study/NN
is/VBZ
the/DT
first/JJ
study/NN
to/TO
investigate/VB
the/DT
association/NN
between/IN
IFI6/NN
polymorphisms/NNS
and/CC
HBV/NN
clearance/NN
as/IN
an/DT
ISG/NN
./.
====================
In/IN
addition/NN
,/,
SR/JJ
patients/NNS
were/VBD
used/VBN
as/IN
controls/NNS
instead/RB
of/IN
normal/JJ
healthy/JJ
subjects/NNS
to/TO
show/VB
the/DT
effect/NN
of/IN
genomic/JJ
background/NN
on/IN
the/DT
chronicity/NN
of/IN
HBV/NN
infection/NN
./.
====================
Normal/JJ
controls/NNS
that/DT
never/RB
contracted/VBD
HBV/NN
are/VBP
not/RB
suitable/JJ
to/TO
show/VB
the/DT
genetic/JJ
effects/NNS
./.
====================
Future/JJ
studies/NNS
should/MD
include/VB
a/DT
larger/JJR
sample/JJ
size/NN
and/CC
additional/JJ
information/NN
in/IN
the/DT
replication/NN
study/NN
to/TO
validate/VB
the/DT
significance/NN
of/IN
the/DT
results/NNS
through/IN
epistasis/NN
and/CC
environmental/JJ
interactions/NNS
./.
====================
In/IN
addition/NN
,/,
IFI6/NN
promoter/NN
variations/NNS
should/MD
be/VB
characterized/VBN
using/VBG
next-generation/JJ
sequencing/NN
techniques/NNS
,/,
causal/JJ
variants/NNS
should/MD
be/VB
identified/VBN
,/,
and/CC
mechanisms/NNS
underlying/VBG
the/DT
effect/NN
of/IN
IFI6/NN
on/IN
HBV/NN
clearance/NN
that/DT
is/VBZ
mediated/VBN
by/IN
HBV/NN
antigen-specific/JJ
CD8+/JJ
T/NN
cell/NN
survival/NN
need/RB
to/TO
be/VB
investigated/VBN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
an/DT
initial/JJ
discovery/NN
stage/NN
showed/VBD
that/IN
the/DT
rs2808426/NN
and/CC
rs10902662/NN
genotypes/NNS
and/CC
the/DT
corresponding/JJ
diplotype/JJ
were/VBD
associated/VBN
with/IN
a/DT
higher/JJR
probability/NN
of/IN
HBV/NN
clearance/NN
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
However/RB
,/,
the/DT
results/NNS
could/MD
not/RB
be/VB
replicated/VBN
in/IN
a/DT
second/JJ
stage/NN
with/IN
a/DT
different/JJ
patient/NN
sample/NN
./.
====================
Further/RB
studies/NNS
should/MD
be/VB
aimed/VBN
at/IN
showing/VBG
how/WRB
IFI6/NN
affects/VBZ
HBV/NN
clearance/NN
by/IN
promoting/VBG
HBV/NN
antigen-specific/JJ
CD8+/JJ
T/NN
cell/NN
survival/NN
./.
====================
Moreover/RB
,/,
identification/NN
of/IN
causal/JJ
variants/NNS
in/IN
the/DT
IFI6/NN
by/IN
including/VBG
a/DT
large/JJ
number/NN
of/IN
samples/NNS
may/MD
help/VB
clarify/VB
the/DT
role/NN
of/IN
IFI6/NN
on/IN
HBV/NN
clearance/NN
./.
====================
Clinical/JJ
characteristics/NNS
of/IN
study/NN
subjects/NNS
====================
Genotype/NN
frequencies/NNS
and/CC
associations/NNS
between/IN
SR/JJ
and/CC
CLD/NN
in/IN
IFI6/NN
SNPs/NNS
====================
Diplotype/JJ
frequencies/NNS
and/CC
associations/NNS
between/IN
SR/JJ
and/CC
CLD/NN
in/IN
IFI6/NN
SNPs/NNS
====================
Multistage/JJ
genotype/NN
analysis/NN
of/IN
rs2808426/NN
(/(
C/NN
>/JJR
T/NN
)/)
in/IN
IFI6/NN
gene/NN
====================
